Currently, the first-line treatment for diabetic macular edema (DME), a condition that leads to severe visual impairment in 28–29% of patients with diabetes mellitus (1), is anti-vascular endothelial growth factor (VEGF) therapy (2). The gene discussed is VEGFA; the disease is diabetic macular edema.